Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
61
resultados
Última actualización
08/08/2025 [07:48:00]
Resumen de: US2025251407A1
A monoclonal antibody composition comprises a capture antibody AB7G and a detection antibody AB11A2 for using in preparation of a kit for quantitative detection of amyloid in human body fluids, and the antibodies are monoclonal antibodies secreted by cultured hybridoma cells. The kit specifically recognizes an Aβ42 oligomer, with a linear detection range of 3.9-125 pg/mL, and a lowest detection limit of 7.8 pg/mL. A core technique for kit assembly lies in that the monoclonal antibody AB7G is fixed on a microplate to serve as the capture antibody, and the monoclonal antibody AB11A2 is labeled and then diluted at 1:2000 to serve as the detection antibody. Meanwhile, the present invention relates to heavy and light chain variable region genes of the monoclonal antibodies AB7G and AB11A2 and peptides encoded thereby.
Resumen de: AU2023351193A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Resumen de: WO2024069193A1
The invention relates to methods of screening for the presence of proteopathies, to methods of diagnosing proteopathies, to methods of differentially diagnosing proteopathies, to methods of assessing the severity, stage and/or prognosis of proteopathies, and to methods for monitoring the progression of proteopathies. The invention also relates to methods for determining the efficacy of therapeutic interventions for proteopathies.
Resumen de: MX2025008034A
The present disclosure provides anti-amyloid β (Aβ) antibodies and antibody fragments that preferentially bind soluble amyloid Aβ protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid β (Aβ) antibodies and antibody fragments that reduce soluble amyloid Aβ protofibril/oligomer levels and insoluble amyloid Aβ plaque in brain tissue, and the use of anti-Aβ protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with Aβ protein aggregation, in particular Alzheimer's disease (AD).
Resumen de: US2025244342A1
The disclosure relates to methods and kits for detecting tau, e.g., tau that is phosphorylated at amino acid position T181 (pTau181), tau that is phosphorylated at amino acid position T217 (pTau217), and/or total tau. The disclosure further provides methods for distinguishing between individuals whose cognitive condition will remain stable and whose cognitive condition will decline during their lifetime. The disclosure also provides methods for determining the eligibility of individuals for participation in clinical trials for Alzheimer's disease treatments. Also provided are methods for distinguishing between individuals with Alzheimer's disease and non-Alzheimer's dementia, and for monitoring response to treatment for Alzheimer's disease.
Resumen de: WO2025159608A1
The present invention relates to the identification of a target material through which Porphyromonas gingivalis affects dementia, and a use of a Porphyromonas gingivalis vaccine for preventing or treating dementia. A composition comprising (Porphyromonas gingivalis, of the present invention, reduces the expression of IGFBP2, Aß and p-Tau and reduces the level of blood insulin, and thus can be used as an effective composition for a dementia vaccine or a composition for preventing, alleviating or treating dementia, and can be effectively used in a method for preventing or treating dementia.
Resumen de: MX2025003197A
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: EP4592679A1
The present invention discloses use of an agent for detecting the expression level of discoidin domain receptor 2 (DDR2) in the preparation of a kit for diagnosing a neurodegenerative disease in a subject, wherein the level of DDR2 in a sample from the subject being higher than the level of a control not having the disease indicates that the subject has the neurodegenerative disease. The present invention also discloses a kit and a method for diagnosing a neurodegenerative disease, and a computer-readable storage medium. The present invention can efficiently and accurately diagnose the neurodegenerative disease by detecting DDR2.
Resumen de: MX2025005880A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: TW202502373A
The invention provides application of IL-27 protein in preparation of a product for treating Alzheimer's disease, and belongs to the technical field of biological medicine. The IL-27 protein is a recombinant IL-27 protein, and aims at a treatment target IL-27, and comprises a mouse source IL-27, a human source IL-27, and a mammal IL-27 except the mouse source IL-27 and the human source IL-27. The recombinant IL-27 protein provided by the invention can effectively relieve Alzheimer's disease caused by A beta deposition, and can be selectively and specifically combined with a receptor of the recombinant IL-27 protein, so that the accuracy of a detection result is ensured; the specificity of the protein receptor is highly expressed in the dentate gyrus region of the sea horse, so that the drug targeting is ensured to the greatest extent; the recombinant IL-27 protein has a good application prospect, can quickly and effectively improve and relieve memory impairment and other behaviors of mice with Alzheimer's disease, and has a clinical transformation value.
Resumen de: US2025238922A1
Described are platforms, systems, and methods for screening patients. In one aspect, a computer-implemented method comprises: receiving, from a cellular imaging device, image data comprising calcium kinetic features of neuronal cultures derived from a patient; processing the image data through a machine-learning model to determine a diagnosis for the patient based on the calcium kinetic features, the machine-learning model trained using neuronal calcium data; and providing the diagnosis a user interface.
Resumen de: US2025235464A1
Described herein are methods for inhibiting generation of one or more non-classical variant(s) of amyloid precursor protein (APP) gene. Provided herein are methods for diagnosing an individual having or suspected of having Alzheimer's disease following identification of an expression profile or an activity profile of the one or more non-classical variant(s) and treating the individual using a reverse transcriptase inhibitor or salt thereof.
Resumen de: US2025237652A1
Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.
Resumen de: EP4589015A2
In vitro method for the diagnosis of synucleinopathies. The present invention is directed to an in vitro method for the specific diagnosis of a synucleinopathy and/or for the differential diagnosis of a synucleinopathy from Alzheimer disease (AD). In a preferred embodiment, the synucleinopathy is Dementia with Lewy bodies (DLB) or Parkinson's disease (PD).
Resumen de: JP2024037794A
To provide a method for measuring an amount of singly or multiply phosphorylated p217+tau protein in a sample, regarding compositions and methods for detecting neurodegeneration.SOLUTION: A method for measuring a p217+ tau peptide in a sample, comprises: (i) contacting the sample with a capture antibody against a p217+ tau epitope to capture the p217+ tau peptide in the sample; and (ii) contacting the captured p217+ tau peptide with at least one of a first detection antibody against an epitope comprising amino acid residues 119 to 126 of a tau protein and a second detection antibody against an epitope comprising amino acid residues 7 to 20 of the tau protein, and measuring at least one of an amount of the p217+ tau peptide and an amount of a long p217+ tau peptide, where amino acid numbering refers to a specific amino acid sequence.SELECTED DRAWING: None
Resumen de: AU2025204747A1
The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer’s disease. The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease. un u n h e i n v e n t i o n r e l a t e s t o m e t h o d s a n d c o m p o s i t i o n s f o r d e v e l o p i n g b a s a l f o r e b r a i n c h o l i n e r g i c n e u r o n s ( s ) f r o m s t e m c e l l s , a n d i n p a r t i c u l a r , s h a v i n g r e p a i r e d e l e c t r o p h y s i o l o g i c a l d e f e c t s r e l a t i n g t o o n e o r m o r e m u t a t i o n s i n , a n d t o t h e u s e o f s u c h s i n c e l l - b a s e d t h e r a p i e s t o t r e a t l z h e i m e r ' s d i s e a s e
Resumen de: WO2025148411A1
A protein antigen for Alzheimer's disease detection comprises at least any two of DOC2A, LGALS1, KDM4D, and ADARB1 proteins at the same time, can be used for early detection or diagnosis of Alzheimer's disease, and is suitable for risk assessment and prediction of before the onset of Alzheimer's disease; moreover, the protein antigen can distinguish Alzheimer's disease from other types of dementia, and can be further prepared into a related reagent or kit according to requirements.
Resumen de: US2025231178A1
The present disclosure relates to a method for determining a risk of development or risk of presence of Alzheimer's disease in a human subject comprising analyzing an activity of a PIEZO1 receptor. The disclosure also relates to a kit for determining a risk of development or risk of presence of Alzheimer's disease according to the present method. The disclosure also relates to an in vitro use of a PIEZO1 receptor as a biomarker and determination of intracellular calcium level as a biomarker for determining a risk of development or risk of presence of Alzheimer's disease in a human subject.
Resumen de: US2025231201A1
Described herein are biological devices and extracts useful for detecting Alzheimer's disease and/or concussions. The biological devices include microbial cells transformed with a DNA construct containing genes for producing β-amyloid precursor protein, microtubule associated protein tau, adipose triglyceride lipase, acyl-CoA dehydrogenase, and O-linked N-acetylglucosamine transferase. In some instances, the biological devices also include a gene for enhanced green fluorescent protein. Methods for using the devices to diagnose or detect Alzheimer's disease and/or concussions are also provided herein.
Resumen de: WO2024052650A1
The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.
Resumen de: MX2024013690A
The present disclosure provides devices for the detection and/or quantification of neurotoxic amyloid-type protein aggregates, comprising a doxycycline derivative immobilized on an appropriate surface, as well as electrochemical and immunochemical methods associated to the use of such devices.
Resumen de: CN119866443A
Described herein are methods for detecting conformational diseases, aging, and proteinopathies by measuring the presence of b-isox precipitates and the level of b-isox capture proteins in biological fluids of healthy individuals and patients. The studies have identified additional biomarkers that make it possible to detect biomarkers by adding or not adding isoxazole to the obtained biological fluid sample, thereby making it possible to detect, diagnose or treat human diseases in a human subject. Diagnosis of disease using b-isox and/or biomarkers becomes possible.
Resumen de: US2024360206A1
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Resumen de: US2025224408A1
Provided herein are methods, compositions, and systems for diagnosing, assessing the likelihood of Alzheimer's disease, and assessing the rate of progression of Alzheimer's disease comprising assaying biofluid samples and identifying from the biofluid samples the presence/abundance of one or more biomarkers. Also provided herein are methods of assessing the likelihood of dementia progression or the rate of dementia progression comprising assaying biofluid samples and identifying from the biofluid samples the presence/abundance of one or more biomarkers.
Nº publicación: US2025222034A1 10/07/2025
Solicitante:
BIOTECH THERAPEUTICS LLC [US]
Biotech Therapeutics, LLC
Resumen de: US2025222034A1
A method of generating MSC-derived exosome populations may include collecting MSC containing material from living tissue, separating desired mononuclear cells from granulocytes, culturing to multiply the cells, separation of desired cells for further multiplication by washing non-adherent cells and culturing adherent cells, repeating as necessary to obtain a suitably pure population of MSCs, culturing the MSCs in culture media containing negative/healing active cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10) and multifunctional cytokine TGF-ß, and isolating the MSC-derived exosome populations. Diverse MSC-derived exosome populations may be generated by altering the cytokine composition of the culture media. The MSC-derived exosome populations may be screened for effectiveness in treatment of Long Covid using in vitro, in vivo, and pre-clinical testing utilizing model organisms. The exosomes may be administered nasally. Successful MSC-derived exosome populations may be further subjected to patient trials to establish efficacy in treatment of Long Covid via nasal administration of the MSC-derived exosome populations to human subjects. Similar methodologies may be employed to establish efficacy of the MSC-derived exosome populations for treatment of other diseases and conditions related to the central nervous system, spinal cord injury, or neurological diseases, such as Alzheimer disease.
BOPI
Sede Electrónica
